Ilika plc award share options under the long term incentive plan

Ilika plc

Ilika plc (LON:IKA), a pioneer in solid-state battery technology, has announced that on 7 February 2022 it granted nominal value options over 229,759 ordinary shares of 1p each in the Company to Executive Directors under the Long Term Incentive Plan 2018. Each award vests on the achievement of certain performance targets over a three-year period. The options granted represent in aggregate 0.15 per cent of the Company’s issued share capital.

In addition, on 7 February 2022, 20,000 nominal value options previously awarded under the Company’s bonus scheme have been exercised by Steve Boydell, CFO, and the Executive Directors sold 30,000 shares in aggregate, primarily to cover tax liabilities arising from options exercised under the Company’s bonus scheme in 2021 and 2022.

Details of grants issued under the Company’s Long Term Incentive Plan 2018, options exercised and Ordinary Shares sold by each Executive Director are set out in the tables below, together with the total number of Ordinary Shares each Executive Director holds under option and is interested in.

DirectorNumber of options grantedNumber of options exercisedTotal number of Options now heldPer cent. of issued share capital
Graeme Purdy153,5412,362,1131.50
Steve Boydell76,21820,000755,7230.48
DirectorOrdinary shares soldNumber of shares held post salePer cent. of issued share capital
Graeme Purdy15,000782,9270.50
Steve Boydell15,00058,3460.04

EMI option scheme

Following the vesting of options under Ilika’s EMI share option schemes, 52,500 options with an exercise price of 21p, together with 265,000 options with an exercise price of 18.2p, have been converted into Ordinary shares of 1p each. 

Accordingly, to satisfy options exercised under both the Company’s EMI share option schemes and bonus scheme, the Company has applied to the London Stock Exchange for 337,500 Ordinary Shares to be admitted to trading on AIM. It is expected that Admission will occur at 8.00am on 11 February 2022.

Total Voting Rights

Following Admission, the Ilika issued share capital will comprise 157,217,043 Ordinary Shares and may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules. The Company does not hold any shares in treasury. 

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika’s Stereax batteries set for Medical Technology Ireland showcase

Ilika’s Stereax batteries will be showcased by Cirtec Medical at Medical Technology Ireland, giving the company targeted exposure in the medical device market.

Ilika CEO Graeme Purdy discusses Stereax revenues and Goliath opportunities

Ilika CEO Graeme Purdy discusses first Stereax revenues, grant support for Goliath, EV market trends, and opportunities in defence and e-bikes.

Ilika positions solid state batteries for the future of implantable neurostimulation

Ilika’s Stereax solid state battery technology supports the development of smaller, safer and more practical implantable neurostimulation devices for emerging medical applications.

Ilika advances manufacturing readiness for solid-state batteries

Ilika’s collaboration with UKBIC shows how manufacturing validation is helping move its Goliath pouch cell technology closer to commercial readiness.

Ilika reports first Stereax revenues and Goliath progress

Ilika expects FY26 revenue of approximately ÂŁ1.1m, including first commercial Stereax electrode sales, with Goliath evaluation activity expanding across automotive, defence and e-bike applications.

Search